ClinicalTrials.gg
CompletedNCT00134498Updated Nov 16, 2007

A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides

A Phase 3 interventional study of torcetrapib/atorvastatin and atorvastatin in Hypertriglyceridemia and Hyperlipoproteinemia Type IV, sponsored by Pfizer. Completed at 44 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-11-16.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 150 studies in Hypertriglyceridemia with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hypertriglyceridemia · United States.

Enrollment
31st of 145
160 · median 52
Started
2005
with 3 others
Phase 3
27 of 150
1 open now
Registered
10th of 150
by date

Among the 150 studies in Hypertriglyceridemia with a site in United States, this one is the 31st largest by enrollment of the 145 interventional ones that give a count, is one of 4 that started in 2005, is one of 27 in phase 3, and was the 10th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

10 of the 150 studies in Hypertriglyceridemia with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Hypertriglyceridemia with a site in United States, or all of them as a file.
02

Study summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia.

Read the detailed description

For additional information please call: 1-800-718-1021

03

Conditions studied

  • Hypertriglyceridemia
  • Hyperlipoproteinemia Type IV

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Fredrickson Type IV Hypertriglyceridemia

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating, or planning to become pregnant.
  • Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
  • Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
  • Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
160 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Change in HDL-C and non-HDL-C levels

Secondary outcomes

  1. Changes in levels of other lipid and biomarkers.

07

Study locations

44 sites
  • Pfizer Investigational Site
    Anaheim, California, United States
  • Pfizer Investigational Site
    Huntington Beach, California, United States
  • Pfizer Investigational Site
    Los Angeles, California, United States
  • Pfizer Investigational Site
    Orangevale, California, United States
  • Pfizer Investigational Site
    Orange, California, United States
  • Pfizer Investigational Site
    Pacific Palisades, California, United States
  • Pfizer Investigational Site
    Studio City, California, United States
  • Pfizer Investigational Site
    Tustin, California, United States
  • Pfizer Investigational Site
    Walnut Creek, California, United States
  • Pfizer Investigational Site
    Farmington, Connecticut, United States
  • Pfizer Investigational Site
    Washington, District of Columbia, United States
  • Pfizer Investigational Site
    Hollywood, Florida, United States
  • Pfizer Investigational Site
    Longwood, Florida, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida, United States
  • Pfizer Investigational Site
    Tripler AMC, Hawaii, United States
  • Pfizer Investigational Site
    Chicago, Illinois, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana, United States
  • Pfizer Investigational Site
    Overland Park, Kansas, United States
  • Pfizer Investigational Site
    Baton Rouge, Louisiana, United States
  • Pfizer Investigational Site
    Scarborough, Maine, United States
  • Pfizer Investigational Site
    Bethesda, Maryland, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan, United States
  • Pfizer Investigational Site
    Canton, Michigan, United States
  • Pfizer Investigational Site
    Portage, Michigan, United States
  • Pfizer Investigational Site
    Richland, Michigan, United States
  • Pfizer Investigational Site
    St. Cloud, Minnesota, United States
  • Pfizer Investigational Site
    Olive Branch, Mississippi, United States
  • Pfizer Investigational Site
    Jefferson City, Missouri, United States
  • Pfizer Investigational Site
    St. Louis, Missouri, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada, United States
  • Pfizer Investigational Site
    Rochester, New York, United States
  • Pfizer Investigational Site
    Syracuse, New York, United States
  • Pfizer Investigational Site
    West Seneca, New York, United States
  • Pfizer Investigational Site
    Statesville, North Carolina, United States
  • Pfizer Investigational Site
    Sellersville, Pennsylvania, United States
  • Pfizer Investigational Site
    Warwick, Rhode Island, United States
  • Pfizer Investigational Site
    San Antonio, Texas, United States
  • Pfizer Investigational Site
    Richmond, Virginia, United States
  • Pfizer Investigational Site
    Madison, Wisconsin, United States
  • Pfizer Investigational Site
    Halifax, Nova Scotia, Canada
  • Pfizer Investigational Site
    London, Ontario, Canada
  • Pfizer Investigational Site
    Chicoutimi, Quebec, Canada
  • Pfizer Investigational Site
    Montreal, Quebec, Canada
  • Pfizer Investigational Site
    Ste-Foy, Quebec, Canada
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2005
First posted
Aug 24, 2005
Start
Feb 2005
Completion
Nov 2006
Last update
Nov 16, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Nov 16, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00134498
Lead sponsor
Pfizer
First posted
Aug 24, 2005
Start date
Feb 2005
Completion
Nov 2006
Last update
Nov 16, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Torcetrapib · Atorvastatin

Start the discussion